
  
    
      
        Background_NNP
        CFEOM_NNP 1_CD is_VBZ an_DT autosomal_NN dominant_JJ disorder_NN that_WDT has_VBZ been_VBN
        linked_VBN to_TO the_DT pericentromere_NN of_IN chromosome_NN 12_CD ,_, flanked_JJ by_IN
        marker_NN D_NNP 12_CD S_NNP 1584_CD on_IN the_DT p_NN arm_NN and_CC D_NNP 12_CD S_NNP 1668_CD on_IN the_DT q_NN arm_NN [_NN 1_CD ,_,
        2_CD ]_NN ._. The_DT clinical_JJ phenotype_NN consists_VBZ of_IN congenital_NN ,_,
        bilateral_JJ ptosis_NNS and_CC external_JJ ophthalmoplegia_NN ,_, with_IN the_DT
        eyes_NNS partially_RB or_CC completely_RB fixed_VBN in_IN a_DT hypotrophic_JJ or_CC
        downward_JJ position_NN ._. On_IN autopsy_NN ,_, CFEOM_NNP 1_CD patients_NNS appear_VBP to_TO be_VB
        lacking_VBG the_DT superior_JJ division_NN of_IN cranial_NN nerve_NN III_NNP ,_, which_WDT
        innervates_NNS the_DT levator_NN and_CC superior_JJ rectus_JJ muscles_NNS [_NN 3_CD ]_NN ._.
        Whether_IN this_DT disease_NN is_VBZ caused_VBN by_IN a_DT primary_JJ defect_NN in_IN the_DT
        nerve_NN or_CC the_DT muscle_NN remains_VBZ unclear_JJ ._. The_DT disease_NN was_VBD
        initially_RB linked_VBN to_TO an_DT 8_CD centiMorgan_NN region_NN spanning_VBG the_DT
        centromere_NN of_IN chromosome_NN 12_CD ,_, and_CC then_RB further_RBR refined_VBN to_TO a_DT
        critical_JJ region_NN of_IN 3_CD cM_NN [_NN 1_CD ,_, 2_CD ]_NN ._. Yeast_NN and_CC bacterial_JJ
        artificial_JJ chromosome_NN (_( YAC_NNP and_CC BAC_NNP )_) contigs_NNS have_VBP been_VBN
        generated_VBN and_CC a_DT positional_JJ cloning_VBG approach_NN to_TO identify_VB the_DT
        CFEOM_NNP 1_CD causative_JJ gene_NN is_VBZ ongoing_JJ ._.
        Sarcospan_NNP is_VBZ a_DT member_NN of_IN the_DT dystrophin_NN associated_VBN
        protein_NN complex_JJ present_NN in_IN skeletal_NN and_CC extraocular_NN muscle_NN
        [_NN 4_CD ,_, 5_CD ,_, 6_CD ]_NN ._. Sarcospan_NNP is_VBZ most_RBS tightly_RB associated_VBN with_IN the_DT
        transmembrane_NN sarcoglycan_NN subcomplex_NN ,_, mutation_NN of_IN which_WDT
        causes_NNS autosomal_NN recessive_JJ limb_NN girdle_NN muscular_JJ dystrophy_NN
        (_( LGMD_NNP 2_CD C-_NNP 2_CD F_NN )_) [_NN 7_CD ,_, 8_CD ,_, 9_CD ,_, 10_CD ,_, 11_CD ]_NN ._. Primary_JJ mutation_NN of_IN α_NN -_: δ_NN
        sarcoglycan_NN leads_VBZ to_TO a_DT variable_JJ degree_NN of_IN secondary_JJ
        instability_NN of_IN sarcospan_NN and_CC the_DT non-mutant_JJ sarcoglycans_NNS ._.
        Sarcospan_NNP is_VBZ homologous_RB to_TO the_DT tetraspanin_NN superfamily_RB ,_,
        members_NNS of_IN which_WDT have_VBP been_VBN shown_VBN to_TO facilitate_VB both_DT
        integral-membrane_JJ and_CC membrane-proximal_JJ protein_NN
        interactions_NNS involved_VBN in_IN many_JJ different_JJ cellular_JJ processes_VBZ
        [_NN 12_CD ]_NN ._. Sarcospan_NNP had_VBD previously_RB been_VBN identified_VBN as_IN Krag_NNP ,_, a_DT
        gene_NN that_WDT is_VBZ co-amplified_JJ with_IN Ki-ras_NNP in_IN the_DT Y_NNP 1_CD murine_NN
        adrenal_NN carcinoma_NN cell_NN line_NN [_NN 13_CD ,_, 14_CD ]_NN ._. Portions_NNP of_IN the_DT
        gene_NN 's_POS genomic_JJ structure_NN were_VBD elucidated_JJ at_IN that_DT time_NN ,_, and_CC
        the_DT gene_NN was_VBD localized_VBN to_TO chromosome_NN 12_CD p_NN 11_CD ._. 2_LS ._.
        Given_VBN the_DT genomic_JJ localization_NN of_IN sarcospan_NN in_IN the_DT
        critical_JJ region_NN defined_VBN for_IN CFEOM_NNP 1_CD ,_, and_CC its_PRP$ association_NN
        with_IN other_JJ proteins_NNS known_VBN to_TO be_VB involved_VBN in_IN muscular_JJ
        diseases_NNS ,_, sarcospan_NN has_VBZ been_VBN proposed_VBN as_IN a_DT candidate_NN
        disease_NN gene_NN for_IN CFEOM_NNP 1_CD [_NN 5_CD ]_NN ._. We_PRP have_VBP refined_VBN the_DT
        previously_RB published_VBN genomic_JJ structure_NN of_IN sarcospan_NN more_RBR
        fully_RB and_CC screened_VBD for_IN mutations_NNS in_IN six_CD families_NNS with_IN
        CFEOM_NNP 1_CD ._. We_PRP have_VBP also_RB generated_VBN antibodies_NNS that_WDT recognize_VBP
        human_JJ sarcospan_NN and_CC examined_VBD extraocular_NN muscle_NN samples_NNS
        from_IN CFEOM_NNP 1_CD patients_NNS ._.
        We_PRP find_VBP sarcospan_NN to_TO be_VB unmutated_JJ in_IN all_DT six_CD CFEOM_NNP 1_CD
        families_NNS studied_VBN and_CC sarcospan_NN immunoreactivity_NN to_TO be_VB
        identical_JJ in_IN control_NN and_CC CFEOM_NNP 1_CD extraocular_NN muscle_NN ._.
        Sarcospan_NNP is_VBZ also_RB shown_VBN to_TO map_VB electronically_RB to_TO BACs_NNP that_WDT
        are_VBP considered_VBN to_TO be_VB outside_IN of_IN the_DT CFEOM_NNP 1_CD critical_JJ region_NN ._.
        These_DT data_NNS make_VBP it_PRP unlikely_JJ that_DT sarcospan_NN ,_, or_CC other_JJ
        dystrophin_NN associated_VBN proteins_NNS ,_, are_VBP involved_VBN in_IN the_DT
        pathogenesis_NNS of_IN CFEOM_NNP 1_CD ._.
      
      
        Results_NNS
        
          Genomic_NNP organization_NN of_IN the_DT human_JJ sarcospan_NN
          gene_NN
          Five_CD independent_JJ clones_NNS were_VBD isolated_VBN from_IN a_DT human_JJ
          genomic_JJ phage_NN library_NN using_VBG hybridization_NN probes_NNS that_WDT
          covered_VBD the_DT entire_JJ coding_VBG region_NN of_IN sarcospan_NN ._. Primers_NNP
          within_IN the_DT coding_VBG sequence_NN were_VBD designed_VBN to_TO cross_VB the_DT two_CD
          known_VBN intron-exon_JJ junctions_NNS and_CC other_JJ hypothesized_VBN
          junctions_NNS ._. The_DT sarcospan_NN open_JJ reading_NN frame_NN is_VBZ encoded_JJ by_IN
          three_CD exons_NNS ._. The_DT first_JJ exon_NN contains_VBZ 279_CD base_NN pairs_NNS (_( bp_NN )_)
          of_IN coding_VBG sequence_NN and_CC is_VBZ extremely_RB G_NNP /_NN C_NNP rich_JJ (_( 71_CD %_NN )_) ._. The_DT
          second_JJ exon_NN ,_, as_RB previously_RB determined_VBN ,_, is_VBZ 87_CD bp_NN in_IN
          length_NN ._. The_DT third_JJ exon_NN is_VBZ very_RB large_JJ and_CC includes_VBZ the_DT
          last_JJ 363_CD bp_NN of_IN coding_VBG sequence_NN and_CC over_IN 1500_CD bp_NN
          3_CD '_POS -_: untranslated_JJ region_NN (_( UTR_NNP )_) ._.
        
        
          Analysis_NNP of_IN the_DT CFEOM_NNP 1_CD critical_JJ region_NN
          Based_VBN on_IN its_PRP$ cytogenetic_JJ localization_NN and_CC expression_NN
          pattern_NN ,_, sarcospan_NN is_VBZ a_DT candidate_NN gene_NN for_IN autosomal_NN
          dominant_JJ CFEOM_NNP 1_CD ._. Initially_RB ,_, to_TO determine_VB whether_IN
          sarcospan_NN was_VBD contained_VBN on_IN YACs_NNP or_CC BACs_NNP spanning_VBG the_DT
          CFEOM_NNP 1_CD critical_JJ region_NN ,_, YACs_NNP 766_CD h_NN 7_CD ,_, 762_CD e_SYM 1_CD ,_, 951_CD h_NN 6_CD ,_, 813_CD h_NN 9_CD ,_,
          782_CD e_SYM 8_CD ,_, 813_CD g_SYM 11_CD ,_, 832_CD f_SYM 4_CD ,_, 887_CD g_SYM 10_CD ,_, 916_CD c_SYM 8_CD ,_, 936_CD f_SYM 5_CD ,_, 946_CD d_SYM 5_CD ,_, 852_CD c_SYM 3_CD ,_,
          723_CD h_NN 3_CD ,_, 906_CD f_SYM 9_CD ,_, 798_CD b_SYM 12_CD ,_, 958_CD b_SYM 2_CD ,_, 943_CD f_SYM 6_CD ,_, 957_CD b_SYM 8_CD ,_, and_CC 973_CD h_NN 3_CD [_NN 2_CD ]_NN
          and_CC BACs_NNP B_NNP 455_CD J_NNP 16_CD ,_, B_NNP 50_CD I_PRP 19_CD ,_, B_NNP 459_CD A_DT 22_CD ,_, B_NNP 392_CD F_NN 18_CD ,_, B_NNP 193_CD D_NNP 8_CD ,_,
          B_NNP 855_CD O_NNP 3_CD ,_, B_NNP 460_CD N_NNP 10_CD ,_, B_NNP 351_CD C_NNP 12_CD ,_, B_NNP 56_CD H_NNP 16_CD ,_, B_NNP 937_CD H_NNP 2_CD ,_, B_NNP 1035_CD D_NNP 8_CD ,_,
          B_NNP 251_CD K_NNP 10_CD ,_, B_NNP 152_CD M_NNP 7_CD ,_, B_NNP 396_CD F_NN 22_CD ,_, B_NNP 45_CD D_NNP 10_CD ,_, B_NNP 471_CD G_NNP 7_CD ,_, B_NNP 520_CD I_PRP 18_CD ,_, and_CC
          B_NNP 367_CD O_NNP 10_CD (_( AECOM_NNP Genome_NNP Center_NNP Home_NNP Page_NNP chromosome_NN 12_CD maps_NNS
          http_NN :_: /_NN /_NN sequence_NN ._. aecom_NN ._. yu_NN ._. edu_NN /_NN chr_NN 12_CD /_NN QARM_NNP 1_CD ._. pdfand_NN
          http_NN :_: /_NN /_NN sequence_NN ._. aecom_NN ._. yu_NN ._. edu_NN /_NN chr_NN 12_CD /_NN Parm_NNP 2_CD ._. pdf_NN )_) were_VBD
          tested_VBN ._. Positive_JJ control_NN primers_NNS were_VBD able_JJ to_TO amplify_VB
          fragments_NNS of_IN the_DT YACs_NNP and_CC BACs_NNP while_IN sarcospan_NN primers_NNS
          were_VBD not_RB (_( data_NNS not_RB shown_VBN )_) ._.
        
        
          Mutation_NNP Analysis_NNP
          Although_IN the_DT coverage_NN of_IN the_DT YAC_NNP and_CC BAC_NNP physical_JJ maps_NNS
          was_VBD nearly_RB complete_JJ ,_, only_RB direct_JJ sequencing_VBG of_IN CFEOM_NNP 1_CD
          patient_NN DNA_NNP would_MD yield_VB definitive_JJ results_NNS about_IN the_DT
          status_NN of_IN the_DT sarcospan_NN gene_NN in_IN CFEOM_NNP 1_CD ._. Primer_NNP pairs_NNS to_TO
          amplify_VB all_DT of_IN exon_NN 2_CD and_CC the_DT coding_VBG portions_NNS of_IN exons_NNS 1_CD
          and_CC 3_CD were_VBD designed_VBN ._. Because_IN of_IN the_DT large_JJ 3_CD '_POS -_: UTR_NNP present_JJ
          in_IN exon_NN 3_CD ,_, a_DT primer_NN pair_NN was_VBD designed_VBN to_TO amplify_VB the_DT
          coding_VBG portions_NNS of_IN the_DT exon_NN including_VBG the_DT 5_CD '_POS splice_NN
          junction_NN and_CC 40_CD bp_NN of_IN 3_CD '_POS non-coding_JJ sequence_NN (_( Figure_NN
          1_LS )_) ._.
          Two_CD affected_VBN individuals_NNS from_IN each_DT of_IN six_CD families_NNS
          with_IN CFEOM_NNP 1_CD were_VBD analyzed_VBN by_IN direct_JJ sequencing_VBG ._. No_DT
          mutations_NNS or_CC polymorphisms_NNS were_VBD found_VBN ._.
        
        
          Immunofluorescence_NNP Analysis_NNP
          Samples_NNP of_IN CFEOM_NNP 1_CD affected_VBN and_CC unaffected_JJ extraocular_NN
          muscle_NN were_VBD analyzed_VBN for_IN the_DT pattern_NN of_IN sarcospan_NN
          staining_VBG ._. Muscle_NNP was_VBD simultaneously_RB stained_JJ with_IN
          anti-spectrin_JJ antibody_NN so_IN that_IN the_DT samples_NNS '_POS membrane_NN
          integrity_NN could_MD be_VB assessed_VBN ,_, and_CC a_DT comparison_NN could_MD be_VB
          made_VBN between_IN the_DT levels_NNS of_IN sarcospan_NN in_IN normal_JJ and_CC CFEOM_NNP 1_CD
          samples_NNS ._. All_DT samples_NNS showed_VBD normal_JJ sarcolemmal_NN staining_VBG ;_:
          no_DT abnormalities_NNS were_VBD observed_VBN (_( Figure_NN 2_LS )_) ._.
        
        
          BAC_NNP Mapping_NNP of_IN Sarcospan_NNP
          Comparison_NNP of_IN the_DT sarcospan_NN coding_VBG sequence_NN (_( GenBank_NNP
          accession_NN number_NN AF_NNP 016028_CD )_) to_TO the_DT human_JJ genome_NN sequence_NN
          revealed_VBD that_DT sarcospan_NN is_VBZ contained_VBN on_IN the_DT BACs_NNP B_NNP 283_CD G_NNP 6_CD
          and_CC B_NN 612_CD B_NNP 6_CD (_( Chromosome_NNP 12_CD p_NN map_NN page_NN 1_CD
          http_NN :_: /_NN /_NN sequence_NN ._. aecom_NN ._. yu_NN ._. edu_NN /_NN chr_NN 12_CD /_NN Parm_NNP 2_CD ._. pdf_NN )_) ._. These_DT BACs_NNP
          are_VBP located_VBN 48_CD ._. 1_LS cM_NN from_IN the_DT telomere_NN of_IN 12_CD p_NN ,_, while_IN the_DT
          CFEOM_NNP 1_CD critical_JJ region_NN is_VBZ between_IN 53_CD ._. 3_LS and_CC 56_CD ._. 5_LS cM_NN
          (_( Chromosome_NNP 12_CD p_NN map_NN page_NN 3_CD (_( search_NN for_IN D_NNP 12_CD S_NNP 1584_CD )_)
          http_NN :_: /_NN /_NN sequence_NN ._. aecom_NN ._. yu_NN ._. edu_NN /_NN chr_NN 12_CD /_NN Parm_NNP 2_CD ._. pdfand_NN
          Chromosome_NNP 12_CD q_NN map_NN page_NN 1_CD (_( search_NN for_IN D_NNP 12_CD S_NNP 1668_CD )_)
          http_NN :_: /_NN /_NN sequence_NN ._. aecom_NN ._. yu_NN ._. edu_NN /_NN chr_NN 12_CD /_NN QARM_NNP 1_CD ._. pdf_NN )_) ,_, thus_RB
          placing_VBG sarcospan_NN outside_IN of_IN the_DT CFEOM_NNP 1_CD critical_JJ
          region_NN ._.
        
      
      
        Discussion_NNP
        The_DT critical_JJ region_NN for_IN the_DT congenital_NN eye_NN movement_NN
        disorder_NN ,_, CFEOM_NNP 1_CD ,_, has_VBZ been_VBN reduced_VBN to_TO a_DT 3_CD cM_NN region_NN at_IN the_DT
        centromere_NN of_IN human_JJ chromosome_NN 12_CD [_NN 2_CD ]_NN ._. In_IN an_DT effort_NN to_TO
        identify_VB the_DT gene_NN which_WDT when_WRB mutated_VBN gives_VBZ rise_NN to_TO CFEOM_NNP 1_CD ,_,
        a_DT combination_NN of_IN positional_JJ and_CC candidate_NN gene_NN approaches_NNS
        has_VBZ been_VBN undertaken_VBN ._. The_DT sarcospan_NN gene_NN is_VBZ composed_VBN of_IN
        three_CD exons_NNS that_WDT are_VBP located_VBN on_IN human_JJ chromosome_NN 12_CD p_NN 11_CD ._. 2_LS
        and_CC the_DT sarcospan_NN protein_NN has_VBZ been_VBN shown_VBN to_TO be_VB an_DT integral_JJ
        component_NN of_IN the_DT sarcoglycan_NN complex_JJ [_NN 5_CD ,_, 15_CD ,_, 16_CD ]_NN ._.
        Mutations_NNP in_IN any_DT one_CD of_IN the_DT other_JJ four_CD members_NNS of_IN this_DT
        complex_JJ have_VBP been_VBN shown_VBN to_TO cause_VB muscular_JJ dystrophy_NN ._. As_IN the_DT
        extraocular_NN muscle_NN is_VBZ one_CD of_IN the_DT few_JJ muscles_NNS spared_VBN in_IN
        Duchenne_NNP Muscular_NNP Dystrophy_NNP ,_, the_DT dystrophin_NN associated_VBN
        protein_NN complex_JJ present_NN in_IN extraocular_NN muscle_NN may_MD respond_VB
        differently_RB to_TO mutation_NN of_IN the_DT complex_NN than_IN other_JJ striated_JJ
        muscle_NN [_NN 17_CD ,_, 18_CD ]_NN ._. By_IN virtue_NN of_IN its_PRP$ genomic_JJ localization_NN and_CC
        expression_NN in_IN extraocular_NN muscle_NN ,_, sarcospan_NN is_VBZ a_DT candidate_NN
        gene_NN for_IN autosomal_NN dominant_JJ CFEOM_NNP 1_CD ._. We_PRP therefore_RB chose_VBD to_TO
        study_VB sarcospan_NN more_RBR closely_RB within_IN the_DT context_NN of_IN this_DT
        disease_NN ._.
        Immunofluorescence_NNP data_NNS showed_VBD comparable_JJ patterns_NNS of_IN
        sarcospan_NN staining_VBG in_IN CFEOM_NNP 1_CD and_CC control_NN patient_NN samples_NNS
        implying_VBG that_IN there_EX was_VBD no_DT haplo-insufficiency_JJ ,_, altered_VBN
        accumulation_NN or_CC increased_VBN degradation_NN of_IN the_DT sarcospan_NN
        protein_NN in_IN these_DT patients_NNS ._. Direct_NNP sequencing_VBG of_IN the_DT three_CD
        coding_VBG exons_NNS of_IN sarcospan_NN in_IN CFEOM_NNP 1_CD patients_NNS confirmed_VBD that_IN
        they_PRP were_VBD normal_JJ ,_, rendering_VBG alteration_NN of_IN the_DT sarcospan_NN
        protein_NN as_IN the_DT primary_JJ genetic_JJ defect_NN in_IN CFEOM_NNP 1_CD unlikely_JJ ._.
        This_DT conclusion_NN is_VBZ supported_VBN by_IN the_DT electronic_JJ localization_NN
        of_IN sarcospan_NN to_TO BACs_NNP outside_IN of_IN the_DT CFEOM_NNP 1_CD critical_JJ
        region_NN ._.
        The_DT normal_JJ staining_VBG pattern_NN of_IN sarcospan_NN in_IN the_DT
        autosomal_NN dominant_JJ CFEOM_NNP 1_CD patient_NN muscle_NN indicates_VBZ that_IN the_DT
        primary_JJ genetic_JJ mutation_NN is_VBZ likely_JJ to_TO be_VB found_VBN in_IN another_DT ,_,
        unrelated_JJ gene_NN ._. Patients_NNS with_IN autosomal_NN dominant_JJ limb_NN
        girdle_NN muscular_JJ dystrophy_NN type_NN 1_CD C_NNP ,_, caused_VBN by_IN mutations_NNS in_IN
        caveolin-_NN 3_CD [_NN 19_CD ,_, 20_CD ]_NN ,_, or_CC autosomal_NN recessive_JJ LGMD_NNP 2_CD B_NNP ,_, caused_VBN
        by_IN mutations_NNS in_IN dysferlin_NN ,_, show_NN normal_JJ dystrophin_NN and_CC
        sarcoglycan-sarcospan_JJ complex_JJ staining_VBG patterns_NNS [_NN 21_CD ]_NN ._.
        Sarcospan_NNP immunoreactivity_NN is_VBZ altered_VBN in_IN both_DT Duchenne_NNP
        Muscular_NNP Dystrophy_NNP and_CC the_DT sarcoglycanopathies_NNS (_( LGMD_NNP 2_CD C-F_NNP )_)
        and_CC appears_VBZ to_TO be_VB very_RB sensitive_JJ to_TO disturbances_NNS in_IN the_DT
        dystrophin_NN associated_VBN protein_NN complex_JJ [_NN 16_CD ]_NN ._. Thus_RB the_DT
        finding_VBG that_DT sarcospan_NN is_VBZ normal_JJ in_IN CFEOM_NNP 1_CD patient_NN muscle_NN
        suggests_VBZ that_DT sarcospan_NN itself_PRP and_CC the_DT rest_NN of_IN the_DT
        dystrophin_NN associated_VBN protein_NN complex_JJ are_VBP not_RB involved_VBN in_IN
        the_DT pathogenesis_NNS of_IN the_DT disease_NN ._.
        A_DT sarcospan_NN null_NN mouse_NN has_VBZ recently_RB been_VBN generated_VBN and_CC
        appears_VBZ to_TO display_VB a_DT normal_JJ phenotype_NN [_NN 22_CD ]_NN ._. This_DT does_VBZ not_RB ,_,
        however_RB ,_, rule_NN out_RP the_DT possibility_NN of_IN sarcospan_NN playing_VBG a_DT
        primary_JJ role_NN in_IN a_DT muscle_NN disorder_NN ._. There_EX may_MD ,_, for_IN example_NN ,_,
        be_VBP a_DT homologous_RB tetraspanin_NN protein_NN that_WDT compensates_VBZ for_IN
        the_DT absence_NN of_IN sarcospan_NN in_IN mice_NNS ,_, but_CC not_RB in_IN humans_NNS ._. There_EX
        is_VBZ ,_, of_IN course_NN ,_, also_RB a_DT difference_NN between_IN complete_JJ absence_NN
        of_IN a_DT protein_NN and_CC a_DT protein_NN with_IN an_DT altered_VBN sequence_NN ._. This_DT
        may_MD hold_VB especially_RB true_JJ ,_, as_IN sarcospan_NN appears_VBZ to_TO be_VB member_NN
        of_IN the_DT tetraspanin_NN family_NN of_IN proteins_NNS ,_, which_WDT have_VBP been_VBN
        described_VBN as_IN molecular_JJ facilitators_NNS ;_: alterations_NNS of_IN such_JJ a_DT
        protein_NN 's_POS sequence_NN could_MD affect_VB the_DT proteins_NNS with_IN which_WDT it_PRP
        interacts_NNS ._. We_PRP are_VBP therefore_RB expanding_VBG our_PRP$ patient_NN analysis_NN
        to_TO include_VB patients_NNS with_IN other_JJ forms_NNS of_IN muscular_JJ
        abnormalities_NNS including_VBG unlinked_JJ muscular_JJ dystrophies_NNS ._.
        The_DT effort_NN to_TO identify_VB the_DT CFEOM_NNP 1_CD disease_NN gene_NN is_VBZ
        continuing_VBG with_IN analysis_NN of_IN other_JJ genes_NNS and_CC expressed_VBD
        sequence_NN tags_NNS from_IN the_DT critical_JJ region_NN at_IN the_DT centromere_NN of_IN
        chromosome_NN 12_CD ._.
      
      
        Conclusions_NNP
        The_DT DNA_NNP sequence_NN analysis_NN and_CC protein_NN immunofluorescence_NN
        results_NNS that_WDT show_NN sarcospan_NN to_TO be_VB normal_JJ in_IN CFEOM_NNP 1_CD
        patients_NNS ,_, combined_VBN with_IN the_DT localization_NN of_IN sarcospan_NN to_TO
        BACs_NNP that_WDT are_VBP outside_IN of_IN the_DT CFEOM_NNP 1_CD critical_JJ region_NN ,_, make_VB
        it_PRP unlikely_JJ that_DT sarcospan_NN is_VBZ involved_VBN in_IN CFEOM_NNP 1_CD ._.
      
      
        Materials_NNS and_CC Methods_NNP
        
          Screening_NNP of_IN Human_NNP Genomic_NNP DNA_NNP Library_NNP
          Two_CD hybridization_NN probes_NNS spanning_VBG the_DT entire_JJ sarcospan_NN
          coding_VBG sequence_NN were_VBD generated_VBN by_IN PCR_NNP amplification_NN of_IN
          sarcospan_NN cDNA_NN amplifying_VBG 366_CD bp_NN
          (_( 5_CD '_POS -_: ATGGGCAAGAACAAGCAGCCACG-_NNP 3_CD '_POS and_CC
          5_CD '_POS -_: TTTCATAGAAAATTGAATACATGTCC-_NNP 3_CD '_POS )_) and_CC 466_CD bp_NN
          (_( 5_CD '_POS -_: GGGCTGGGATCATTGTCTGCT-_NNP 3_CD '_POS and_CC
          5_CD '_POS -_: GGAATTCTTAGATCTTTTGCTGGGG-_NNP 3_CD '_POS )_) ._. The_DT bands_NNS were_VBD excised_VBN
          from_IN 0_CD ._. 8_CD %_NN low-melt_JJ agarose_NN and_CC 20_CD ng_NN of_IN DNA_NNP were_VBD labeled_VBN
          with_IN [_NN α-_NN 32_CD P_NN ]_NN -_: dCTP_NN using_VBG the_DT Life_NNP Technologies_NNPS Random_NNP
          Primers_NNP DNA_NNP Labeling_VBG System_NNP ._. A_DT human_JJ genomic_JJ phage_NN
          library_NN (_( Clontech_NNP )_) was_VBD screened_VBD by_IN hybridization_NN with_IN the_DT
          radiolabeled_JJ products_NNS according_VBG to_TO standard_JJ protocols_NNS ._.
          Briefly_NNP ,_, filters_VBZ were_VBD pre-hybridized_JJ at_IN 65_CD °_NN C_NNP in_IN
          hybridization_NN buffer_NN (_( 5_CD x_SYM SSC_NNP ,_, 50_CD mM_NN NaPO_NNP 
          4_CD ,_, pH_NN 7_CD ._. 4_CD ,_, 2_CD ._. 5_CD x_SYM Denhardt_NNP 's_POS Solution_NN )_)
          with_IN 100_CD μg_NN /_NN ml_NN denatured_JJ salmon_NN sperm_NN DNA_NNP for_IN two_CD hours_NNS ._.
          Probes_NNP were_VBD denatured_JJ at_IN 95_CD °_NN C_NNP for_IN 5_CD minutes_NNS and_CC added_VBD to_TO
          fresh_JJ hybridization_NN buffer_NN at_IN 200_CD ,_, 000_CD cpm_NN /_NN ml_NN buffer_NN for_IN
          16_CD hours_NNS ._. Following_VBG three_CD one-hour_JJ washes_NNS in_IN 2_CD x_SYM SSC_NNP ,_, 0_CD ._. 1_CD %_NN
          SDS_NNP ,_, filters_VBZ were_VBD exposed_VBN for_IN 18_CD -_: 100_CD hours_NNS ._. Positively_NNP
          hybridizing_VBG plaques_NNS were_VBD purified_JJ by_IN limiting_VBG dilution_NN
          and_CC phage_NN DNA_NNP was_VBD isolated_VBN and_CC purified_JJ with_IN the_DT Lambda_NNP
          Maxi_NNP Kit_NNP (_( Qiagen_NNP )_) ._.
        
        
          Determination_NNP of_IN intron-exon_JJ boundaries_NNS
          Five_CD unique_JJ ,_, partially_RB overlapping_VBG genomic_JJ phage_NN
          clones_NNS were_VBD identified_VBN ._. Phage_NNP DNA_NNP was_VBD sequenced_JJ with_IN exon_NN
          specific_JJ primers_NNS on_IN an_DT ABI_NNP automated_VBN sequencer_NN ._. Acquired_VBN
          data_NNS was_VBD analyzed_VBN with_IN the_DT Sequencher_NNP software_NN
          (_( Genecodes_NNP )_) ._. The_DT intron-exon_JJ borders_NNS were_VBD defined_VBN by_IN
          divergence_NN of_IN the_DT cDNA_NN and_CC genomic_JJ sequences_NNS ,_, and_CC by_IN
          their_PRP$ adherence_NN to_TO splice_NN donor_NN and_CC acceptor_NN consensus_NN
          sequences_NNS ._.
        
        
          Patient_NNP material_NN
          Genomic_NNP DNA_NNP extracted_VBD from_IN blood_NN was_VBD used_VBN to_TO screen_VB
          two_CD affected_VBN family_NN members_NNS from_IN each_DT of_IN six_CD previously_RB
          described_VBD pedigrees_NNS [_NN 1_CD ,_, 2_CD ]_NN ._. The_DT patients_NNS included_VBN in_IN our_PRP$
          analysis_NN are_VBP AIII_NNP 13_CD ,_, AIV_NNP 1_CD ;_: BII_NNP 4_CD ,_, BIV_NNP 1_CD ;_: HIII_NNP 17_CD ,_, HIII_NNP 19_CD ;_:
          AAIII_NNP 5_CD ,_, AAIII_NNP 10_CD ;_: ACIV_NNP 5_CD ,_, ACV_NNP 1_CD ;_: and_CC ADIII_NNP 3_CD ,_, ADIII_NNP 8_CD ._.
          Extraocular_NNP muscle_NN (_( inferior_JJ rectus_JJ )_) from_IN patient_NN AVI_NNP 1_CD
          was_VBD obtained_VBN during_IN a_DT diagnostic_JJ biopsy_NN ._. Age_NNP match_VB
          control_NN extraocular_NN muscle_NN (_( inferior_JJ rectus_JJ )_) from_IN an_DT
          unrelated_JJ ,_, unaffected_JJ individual_NN was_VBD obtained_VBN during_IN an_DT
          autopsy_NN ._.
          This_DT study_NN was_VBD approved_VBN by_IN the_DT Children_NNP 's_POS Hospital_NNP
          institutional_JJ review_NN board_NN ,_, and_CC informed_VBD consent_NN was_VBD
          obtained_VBN from_IN all_DT adult_NN participating_VBG subjects_NNS and_CC from_IN
          parents_NNS or_CC legal_JJ guardians_NNS of_IN participating_VBG minors_NNS ._.
        
        
          YAC_NNP and_CC BAC_NNP maps_NNS
          Development_NNP of_IN the_DT YAC_NNP map_NN was_VBD described_VBN previously_RB by_IN
          Engle_NNP ,_, et_CC al_NN ._. [_NN 1_CD ]_NN ._. BACs_NNP were_VBD isolated_VBN from_IN RPCI-_NNP 11_CD male_JJ
          and_CC RPCI-_NNP 13_CD female_JJ BAC_NNP libraries_NNS as_IN described_VBN [_NN 23_CD ,_,
          24_CD ]_NN ._.
        
        
          PCR_NNP amplification_NN from_IN YAC_NNP contig_NN
          Primers_NNP from_IN exons_NNS 1_CD and_CC 3_CD were_VBD used_VBN to_TO test_VB the_DT YACs_NNP
          from_IN the_DT critical_JJ region_NN defined_VBN for_IN CFEOM_NNP 1_CD ._. The_DT exon_NN 1_CD
          primers_NNS amplified_VBN a_DT 116_CD bp_NN fragment_NN
          (_( 5_CD '_POS -_: AAGGAGTGCGGGGAGGAG-_NNP 3_CD '_POS and_CC 5_CD '_POS -_: GCCATGAGGAAGCCCACC-_NNP 3_CD '_POS )_)
          and_CC the_DT exon_NN 3_CD primers_NNS amplified_VBN a_DT 150_CD bp_NN fragment_NN
          (_( 5_CD '_POS -_: TTTGCCGCCCACCACTATTC-_NNP 3_CD '_POS and_CC
          5_CD '_POS -_: TGAAAGTGCCAGTGACGC-_NNP 3_CD '_POS )_) ._. A_DT total_NN of_IN 28_CD cycles_NNS (_( 94_CD °_NN C_NNP /_NN 1_CD
          minute_NN ;_: 57_CD °_NN C_NNP /_NN 1_CD minute_NN ;_: 72_CD °_NN C_NNP /_NN 1_CD minute_NN )_) following_VBG a_DT 4_CD
          minute_NN denaturation_NN was_VBD used_VBN ._.
        
        
          PCR_NNP amplification_NN from_IN BAC_NNP contig_NN
          Primers_NNP for_IN exons_NNS 2_CD and_CC 3_CD were_VBD used_VBN to_TO test_VB the_DT BACs_NNP
          from_IN the_DT critical_JJ region_NN defined_VBN for_IN CFEOM_NNP 1_CD ._.
          Amplifications_NNP were_VBD performed_VBN as_IN described_VBN below_IN ._.
          Positive_JJ control_NN reactions_NNS included_VBD template_NN DNA_NNP isolated_VBD
          from_IN human_JJ genomic_JJ phage_NN that_WDT contained_VBD the_DT appropriate_JJ
          sarcospan_NN exons_NNS ,_, and_CC primers_NNS from_IN the_DT markers_NNS used_VBN to_TO
          order_VB the_DT BAC_NNP map_NN to_TO ensure_VB the_DT quality_NN of_IN the_DT DNA_NNP ._.
          Reactions_NNP were_VBD analyzed_VBN on_IN agarose_NN gels_NNS and_CC scored_VBD for_IN
          presence_NN or_CC absence_NN of_IN the_DT appropriately_RB sized_VBD
          product_NN ._.
        
        
          Primer_NNP sets_NNS and_CC PCR_NNP conditions_NNS for_IN direct_JJ
          sequencing_VBG
          Three_CD primer_NN pairs_NNS amplifying_VBG the_DT coding_VBG portions_NNS of_IN
          exons_NNS 1_CD and_CC 3_CD and_CC all_DT of_IN exon_NN 2_CD were_VBD designed_VBN (_( Table_NNP 1_LS )_) ._.
          Optimal_NNP polymerase_NN chain_NN reaction_NN conditions_NNS were_VBD
          determined_VBN for_IN each_DT of_IN the_DT sets_NNS using_VBG 60_CD -_: 100_CD ng_NN genomic_JJ
          DNA_NNP ._. Optimal_NNP buffer_NN conditions_NNS for_IN the_DT exon_NN 1_CD primer_NN set_VBN
          were_VBD obtained_VBN with_IN the_DT FailSafe_NNP PCR_NNP PreMix_NNP Selection_NN Kit_NNP
          (_( Epicentre_NNP Technologies_NNPS )_) and_CC Buffer_NNP F_NN was_VBD used_VBN in_IN
          conjunction_NN with_IN the_DT FailSafe_NNP PCR_NNP Enzyme_NNP mix_NN ._. PCR_NNP
          amplifications_NNS were_VBD performed_VBN in_IN a_DT 50_CD μl_NN reaction_NN volume_NN
          with_IN 60_CD -_: 100_CD ng_NN genomic_JJ DNA_NNP ,_, 200_CD μM_NN of_IN each_DT dNTP_NN and_CC 1_CD ._. 25_CD
          units_NNS PCR_NNP enzyme_NN mix_NN ._. A_DT total_NN of_IN 35_CD cycles_NNS (_( 94_CD °_NN C_NNP /_NN 20_CD sec_NN ;_:
          61_CD °_NN C_NNP /_NN 20_CD sec_NN ;_: 72_CD °_NN C_NNP /_NN 30_CD sec_NN )_) following_VBG a_DT 4_CD minute_NN
          denaturation_NN step_NN was_VBD used_VBN ._. Exons_NNP 2_CD and_CC 3_CD were_VBD amplified_VBN
          using_VBG PfuTurbo_NNP polymerase_NN (_( Stratagene_NNP )_) at_IN 2_CD ._. 5_CD Units_NNS per_IN
          50_CD μl_NN reaction_NN ,_, containing_VBG 5_CD μl_NN of_IN the_DT accompanying_VBG 10_CD x_SYM
          PCR_NNP buffer_NN ,_, 200_CD μM_NN of_IN each_DT dNTP_NN ,_, 100_CD ng_NN of_IN each_DT primer_NN
          and_CC 60_CD -_: 100_CD ng_NN genomic_JJ DNA_NNP ._. A_DT total_NN of_IN 35_CD cycles_NNS (_( 94_CD °_NN C_NNP /_NN 20_CD
          sec_NN ;_: 56_CD °_NN C_NNP /_NN 20_CD sec_NN ;_: 72_CD °_NN C_NNP /_NN 1_CD min_NN )_) was_VBD used_VBN to_TO amplify_VB both_DT
          exons_NNS 2_CD and_CC 3_CD ._. PCR_NNP amplification_NN products_NNS were_VBD purified_JJ
          using_VBG the_DT QIAquick_NNP PCR_NNP Purification_NNP Kit_NNP (_( Qiagen_NNP )_) and_CC both_DT
          strands_NNS were_VBD sequenced_JJ on_IN an_DT ABI_NNP automated_VBN sequencer_NN ._.
          Data_NNP was_VBD analyzed_VBN with_IN the_DT Sequencher_NNP software_NN
          (_( Genecodes_NNP )_) ._.
        
        
          Antibodies_NNP
          Anti-human-sarcospan_NNP antibodies_NNS were_VBD generated_VBN by_IN
          subcutaneous_JJ injection_NN of_IN New_NNP Zealand_NNP white_JJ rabbits_NNS with_IN
          the_DT synthetic_JJ N-_NNP terminal_NN peptide_NN MGKNKQPRGQQRQGGC_NNP (_( QCB_NNP )_) ._.
          The_DT final_JJ amino_JJ acid_NN was_VBD added_VBN for_IN purification_NN purposes_NNS ._.
          The_DT resulting_VBG serum_NN was_VBD purified_JJ over_IN a_DT peptide_NN affinity_NN
          column_NN made_VBN by_IN covalent_NN coupling_NN of_IN the_DT unlinked_JJ peptide_NN
          to_TO SulfoLink_NNP beads_NNS (_( Pierce_NNP )_) ._. Anti-human_NNP spectrin_NN
          antibodies_NNS (_( NCL-SPEC_NNP 1_LS )_) were_VBD obtained_VBN from_IN Vector_NNP
          Laboratories_NNPS ._.
        
        
          Immunofluorescence_NNP Analysis_NNP
          CFEOM_NNP 1_CD patient_NN and_CC normal_JJ muscle_NN sections_NNS from_IN
          extraocular_NN muscle_NN were_VBD stained_JJ with_IN anti-human_JJ sarcospan_NN
          and_CC anti-human_JJ spectrin_NN antibodies_NNS ._. Sections_NNP were_VBD fixed_VBN
          for_IN 1_CD minute_NN in_IN ice_NN cold_JJ methanol_NN ;_: blocked_VBN for_IN 45_CD minutes_NNS
          in_IN blocking_VBG buffer_NN (_( 15_CD %_NN horse_NN serum_NN ,_, 0_CD ._. 025_CD %_NN Triton_NNP ,_, 1_CD x_SYM
          PBS_NNP )_) ;_: incubated_JJ overnight_JJ at_IN 4_CD °_NN C_NNP with_IN anti-sarcospan_JJ
          (_( 1_CD :_: 750_CD )_) and_CC anti-spectrin_JJ (_( 1_CD :_: 100_CD )_) antibodies_NNS in_IN block_NN
          buffer_NN ;_: washed_VBN 3_CD ×_NN for_IN 15_CD minutes_NNS in_IN wash_NN buffer_NN (_( 0_CD ._. 025_CD %_NN
          Triton_NNP ,_, 1_CD x_SYM PBS_NNP )_) ;_: incubated_JJ for_IN 2_CD hours_NNS at_IN 4_CD °_NN C_NNP with_IN Cy_NNP 3_CD
          conjugated_JJ anti-rabbit_JJ secondary_JJ antibody_NN (_( Jackson_NNP
          ImmunoResearch_NNP )_) and_CC Alexa-_NNP 488_CD conjugated_JJ anti-mouse_JJ
          secondary_JJ antibody_NN (_( Molecular_NNP Probes_NNP Inc_NNP ._. )_) diluted_VBN 1_CD :_: 300_CD
          in_IN blocking_VBG buffer_NN ;_: washed_VBN 3_CD ×_NN for_IN 15_CD minutes_NNS in_IN wash_NN
          buffer_NN and_CC mounted_VBD with_IN Immumount_NNP (_( Shandon_NNP )_) ._. Samples_NNP were_VBD
          examined_VBN using_VBG a_DT Zeiss_NNP Axiophot_NNP microscope_NN ._.
        
      
    
  
